Abstract
Acute myeloid leukemia (AML) diagnosis is increasingly based on the underlying genetic characteristics. While conventional cytogenetic analysis still comprises the backbone of AML classification, evaluation of numerous gene mutations is standard of care for diagnosis, prognostic stratification, and differentially tailored treatment strategies. Genomic technologies have rapidly increased our understanding of the molecular pathogenesis of AML, and this new information is being actively evaluated in comprehensive mutation panels with promise to further improve patient outcomes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
